Literature DB >> 8200438

Basal ganglia GABAA and dopamine D1 binding site correlates of haloperidol-induced oral dyskinesias in rat.

O Shirakawa1, C A Tamminga.   

Abstract

Chronic haloperidol treatment in the laboratory rat induces spontaneous orofacial movements in some but not all of the animals, a behavior which has been described in the literature as vacuous chewing movements (VCMs). In an attempt to understand the neurochemical mechanism of these rat dyskinesias, we measured regional dopamine D1, D2, and GABAA binding density in rats with and without VCMs after chronic haloperidol treatment and in untreated controls using in vitro receptor autoradiography and correlated the binding changes with the dyskinetic behavior. Chronic haloperidol treatment produced an overall increase in dopamine D2 family receptor binding in the caudate putamen and in nucleus accumbens in both groups of treated rats, those with and without VCMs. In the haloperidol-treated rats with VCMs, a significant increase in GABAA receptor density occurred in the substantia nigra pars reticulata (SNR), with a trend in those rats without VCMs. However, only in those haloperidol-treated animals with VCMs did a significant decrease in dopamine D1 receptor density occur in SNR. These receptor alterations are consistent with a process of haloperidol-induced neuronal death of striatonigral fibers. However, we have failed to identify cellular evidence of such toxicity. Alternatively, the receptor changes may reflect increased dendritic dopamine release in SNR, or, more speculatively a functional response to chronically diminished striatonigral pathway activity. Perhaps the release of dopamine from dendrites of the local DA-containing neurons might be variably enhanced with ongoing haloperidol treatment.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8200438     DOI: 10.1006/exnr.1994.1080

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  11 in total

1.  Presynaptic GABAB and adenosine A1 receptors regulate synaptic transmission to rat substantia nigra reticulata neurones.

Authors:  K Z Shen; S W Johnson
Journal:  J Physiol       Date:  1997-11-15       Impact factor: 5.182

2.  The dose-response characteristics of rat oral dyskinesias with chronic haloperidol or clozapine administration.

Authors:  X M Gao; T Hashimoto; T B Cooper; C A Tamminga
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

3.  Effect of alpha lipoic acid on the tardive dyskinesia and oxidative stress induced by haloperidol in rats.

Authors:  Santhrani Thaakur; G Himabindhu
Journal:  J Neural Transm (Vienna)       Date:  2009-05-15       Impact factor: 3.575

4.  The neuropharmacology of psychosis.

Authors:  Carol A Tamminga; John M Davis
Journal:  Schizophr Bull       Date:  2007-06-11       Impact factor: 9.306

5.  Effect of spirulina maxima on the haloperidol induced tardive dyskinesia and oxidative stress in rats.

Authors:  S R Thaakur; B Jyothi
Journal:  J Neural Transm (Vienna)       Date:  2007-05-26       Impact factor: 3.575

6.  Diphenyl diselenide decreases the prevalence of vacuous chewing movements induced by fluphenazine in rats.

Authors:  Roselei Fachinetto; Jardel G Villarinho; Caroline Wagner; Romaiana P Pereira; Robson L Puntel; Márcio W Paixão; Antonio L Braga; João Batista Calixto; João B T Rocha; Juliano Ferreira
Journal:  Psychopharmacology (Berl)       Date:  2007-07-20       Impact factor: 4.530

7.  Time-dependent effects of haloperidol on glutamine and GABA homeostasis and astrocyte activity in the rat brain.

Authors:  Glenn T Konopaske; Nicolas R Bolo; Alo C Basu; Perry F Renshaw; Joseph T Coyle
Journal:  Psychopharmacology (Berl)       Date:  2013-05-10       Impact factor: 4.530

8.  Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model.

Authors:  Souha Mahmoudi; Daniel Lévesque; Pierre J Blanchet
Journal:  Mov Disord       Date:  2014-05-16       Impact factor: 10.338

9.  Treatments for chronic psychosis.

Authors:  C A Tamminga; A C Lahti
Journal:  Dialogues Clin Neurosci       Date:  2001-12       Impact factor: 5.986

10.  Treatment mechanisms: traditional and new antipsychotic drugs.

Authors:  C A Tamminga
Journal:  Dialogues Clin Neurosci       Date:  2000-09       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.